Business
Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery
SOUTH PLAINFIELD, N.J., Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi® (risdiplam) has received multiple
About this update from Ptc Therapeutics, Inc.
[{"type":"text","content":"SOUTH PLAINFIELD, N.J., Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact. The British Pharmacological Society has chosen Evrysdi as the 2022 Drug Discovery of the Year award. In addition, Evrysdi was awarded the 2021 Drug Discovery Prize by the Society for Medicines Research. \n\"Our journey of modulating splicing by small molecules to treat diseases began more than 15 years ago,\" said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. \"At the time, the common dogma espoused that it was not possible to identify oral small molecule drugs that modified splicing. We are excited to see our vision come to fruition, and we are now able to leverage our splicing technology to address multiple other diseases where new treatments are desperately needed. We are honored to have Evrysdi recognized by these awards. More importantly, we are most thrilled by the transformative impact this oral therapy has had on people living with SMA.\" \nEvrysdi was selected from a list of 150 innovative medicines for the British Pharmacological Society's Drug Discovery of the Year award. The Drug Discovery of the Year Award was established by the British Pharmacological Society to celebrate the role pharmacology plays in the development of new medicines and recognize the achievements of groups of medical scientists who research and develop new drugs. The Society for Medicines Research Drug Discovery prize is awarded every three years to a single, novel approved medicine. It recognizes outstanding contributions, achievements, and inventions in the world of drug discovery and development. \nEvrysdi was discovered through PTC's innovative alternative splicing platform. Roche leads the clinical development as part of a collaboration with the SMA Foundation and PTC Therapeutics. Evrysdi is commercialized by Roche and in the United States by Genentech, a member of the Roche Group.\nAbout Spinal Muscular Atrophy (SMA) Spinal muscular atrophy (SMA) is a severe, progressive neuromuscular disease that can be fatal. It affects approximately 1 in 10,000 babies and when untreated is the leading genetic cause of infant mortality. SMA is caused by a mutation of the surviva...